Use of linked data for estimation of the effectiveness of vaccination programs in Queensland

Sarah Sheridan, PhD student
Queensland Children’s Medical Research Institute & School of Population Health, The University of Queensland
Vaccine effectiveness studies involving data linkage

- Rotavirus vaccine effectiveness
- Varicella vaccine effectiveness
- Pertussis vaccine effectiveness
- Hepatitis B assessment of post-exposure prophylaxis for infants born to hep B +ve mothers
Calculation of vaccine effectiveness

• Screening method
  – compares vaccine coverage in cases (PCV) and population (PPV)
  – PPV obtained from Australian Childhood Immunisation Register
  – partially vaccinated children excluded from cases and population
  – possible in QLD (and NT) because both jurisdictions have local immunisation registers

\[
VE = \left(1 - \frac{PCV}{(1 - PCV)} \times \frac{(1 - PPV)}{PPV}\right) \times 100
\]
Rotaviruses (RV)

- most common cause of severe childhood gastroenteritis worldwide
- approximately 450,000 deaths in children <5 years of age
- publicly funded RV vaccination introduced in mid-2007
RV study: aims

• Assess changes in RV epidemiology since commencement of the publicly funded vaccination program using routinely collected health data

• Calculate vaccine effectiveness (VE) of (i) pentavalent RV vaccine in QLD, and (ii) monovalent RV vaccine in NT, in preventing RV notifications, RV and non-RV gastroenteritis hospitalisations and gastroenteritis ED presentations
RV study: methods (QLD)

Data linkage by the Health Statistics Unit:
- Notifiable conditions system (NOCS)
- QLD hospital admitted patient data collection (QHAPDC)
- Emergency department information system (EDIS)
- Auslab (from Pathology QLD)
- Vaccination information and vaccination administration system (VIVAS)
RV study data linkage (QLD)

QHAPDC

EDIS
RV study data linkage (QLD)

NOCS

VIVAS

QHAPDC

EDIS
RV study data linkage (QLD)
RV study data linkage (QLD)

- NOCS
- QHAPDC
- VIVAS
- EDIS
- Auslab
RV study: expected outcomes (QLD)

- RV VE estimates for prevention of notification, ED presentation and hospitalisation for RV and non-RV acute gastroenteritis in children under 5 years between 2009 and 2011, among Indigenous and non-Indigenous children
RV vaccination and febrile seizures

• RV-related illnesses are associated with both febrile and afebrile seizures

• recent retrospective cohort study of US children found a protective association between full RV vaccination and childhood seizures resulting in emergency department (ED) presentation or hospital admission in the year following vaccination [1]

• Using our linked dataset containing febrile, but not afebrile, seizure outcome data, we sought evidence of a similar effect in QLD children

# RV vaccination and febrile seizures: results

<table>
<thead>
<tr>
<th>Birth cohort</th>
<th>Age range</th>
<th>Vaccinated cases</th>
<th>Total cases</th>
<th>PPV (%)</th>
<th>VE [%] (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Any ED presentations for febrile seizures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2007–April 2008; May 2008–April 2009; May 2009–April 2010</td>
<td>8m–2y7m</td>
<td>1301</td>
<td>1530</td>
<td>87.7-90.9</td>
<td>35.8 (26.0 – 44.2)</td>
</tr>
<tr>
<td>May 2007–April 2008; May 2008–April 2009</td>
<td>1yr8m–3y7m</td>
<td>454</td>
<td>544</td>
<td>86.7-90.3</td>
<td>34.7 (18.1 – 48.0)</td>
</tr>
<tr>
<td>May 2007–April 2008</td>
<td>2y8m–4y7m</td>
<td>92</td>
<td>137</td>
<td>85.8</td>
<td>66.2 (51.6 – 76.4)</td>
</tr>
<tr>
<td><strong>Any hospital admissions for febrile seizures</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>May 2007–April 2008; May 2008–April 2009; May 2009–April 2010</td>
<td>8m–2y7m</td>
<td>389</td>
<td>460</td>
<td>87.7-90.9</td>
<td>38.0 (20.1 – 51.9)</td>
</tr>
<tr>
<td>May 2007–April 2008; May 2008–April 2009</td>
<td>1y8m–3y7m</td>
<td>110</td>
<td>142</td>
<td>86.7-90.3</td>
<td>56.4 (35.3 – 70.7)</td>
</tr>
<tr>
<td>May 2007–April 2008</td>
<td>2y8m–4y7m</td>
<td>23</td>
<td>33</td>
<td>85.8</td>
<td>62.0 (19.2 – 82.1)</td>
</tr>
</tbody>
</table>
RV vaccination and febrile seizures: conclusions

- Our results support the recent US finding

- Reduction in seizures from RV vaccination may result in substantial benefits to children, their parents and the health system more broadly
Febrile Seizures in the Era of Rotavirus Vaccine

Sarah L. Sheridan,1,2 Robert S. Ware,1,2 Keith Grimwood,1,3 and Stephen B. Lambert1,4
1Queensland Children’s Medical Research Institute; 2School of Population Health, The University of Queensland, Brisbane; 3Griffith University and Gold Coast University Hospital; and 4Communicable Diseases Unit, Queensland Health, Brisbane, Australia

Corresponding Author: Sarah L. Sheridan, MAAppEpid, Queensland Children’s Medical Research Institute, The University of Queensland, Royal Children’s Hospital, Herston Road, Herston, QLD 4029, Brisbane, Australia. E-mail: s.sheridan@uq.edu.au.

Received July 1, 2014; accepted September 2, 2014.

A protective association between rotavirus vaccination and childhood seizures in the year after vaccination was recently reported from the United States. In the state of Queensland, Australia, the authors found that rotavirus vaccine was 35.8% and 38.0% effective at preventing emergency department presentation and subsequent hospitalization, respectively, for febrile seizures among children up to two years following vaccination.

Key words. rotavirus vaccine; febrile seizures.
Background – chicken-pox and varicella vaccine

• Caused by varicella-zoster virus (VZV)
• Primary infection – chicken-pox, VZV establishes latency in dorsal root ganglia and can reactivate manifesting as herpes zoster
• Usually mild disease occurring in childhood, causing complications in 1% (pneumonia, 2ndy bacterial skin infections, acute cerebellar ataxia, encephalitis)
• More severe in adults and immunocompromised
• Publicly funded varicella vaccine (VV) introduced as an 18-month dose in November 2005
• VV replaced by MMRV at 12-months of age in July 2013
• No assessment of effectiveness of single dose VV in Australia
Varicella VE study

Aim

• Assess the impact and effectiveness of a single dose of varicella vaccine (VV or MMRV) in Queensland
Linked datasets:
1. “NOCS-VIVAS”
2. “QHAPDC-VIVAS”
3. “EDIS-VIVAS”
Expected outcomes and benefits of varicella research

• novel results on persisting VE for single dose of vaccine in Australia from a population based study

• evidence base for decision making about the publicly funded varicella vaccination program, including:
  – providing evidence on which to compare the change in schedule to MMRV vaccine given at 12 months of age, and
  – inclusion of a 2nd dose of varicella vaccine into the National Immunisation Program

• by supporting an evidence based vaccination program, contribute to high uptake of effective vaccines, and reduction in varicella morbidity
Pertussis (whooping cough) studies: aims

Study 1:
• Compare the effectiveness of whole-cell pertussis versus acellular pertussis vaccine

Study 2:
• Assess the absolute effectiveness of acellular pertussis vaccine
Age-specific pertussis notification rates, QLD, 2008-2011

Annual notification rate (per 100,000 per year)

Age (years)
Age-specific pertussis notification rates, QLD, 2008-2011

- **Acellular vaccine use**
- **Whole-cell vaccine use**

Transition from DTPw to DTPa
Pertussis study 1: methods

• Linked pertussis notification (NOCS) and vaccination records (VIVAS)

• Inclusion criteria:
  – born in 1998
  – ≥3 doses of pertussis-containing vaccine <1 year of age
  – QLD vaccine service provider
Pertussis study 1: methods

Children analysed by number and order of DTPw doses <1 year, during 2009-2011

- 3+ DTPw only
- 3+ DTPa only
- mixed-course 3+ doses DTPw/DTPa
  - 1 dose DTPw in 3+ dose course
    - DTPw as 1st dose
    - DTPa as 1st dose
  - 2+ doses of DTPw in 3+ dose course
    - DTPw as 1st dose
    - DTPa as 1st dose
Pertussis study 1: results

• Denominator:
  – 40,694 (69.9%) of 58,233 children born in 1998 with a VIVAS record included in analysis

• Cases:
  • 242 individuals notified as pertussis cases 2009-2011
  • 2 cases had second notifications - excluded

<table>
<thead>
<tr>
<th>Primary-course</th>
<th>Notifications (count)</th>
<th>Average annual incidence-rate&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Incidence-rate ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pure course</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DTPa primary-course (n=9,827)</td>
<td>110</td>
<td>373.1</td>
<td><strong>3.29</strong> (2.44, 4.46)</td>
</tr>
<tr>
<td>DTPw primary-course (n=22,956)</td>
<td>78</td>
<td>113.3</td>
<td>reference</td>
</tr>
<tr>
<td>Mixed course</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose DTPa (n=978)</td>
<td>12</td>
<td>409.0</td>
<td><strong>3.61</strong> (1.79, 6.67)</td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose DTPw (n=6,933)</td>
<td>42</td>
<td>201.9</td>
<td>1.78 (1.20, 2.63)</td>
</tr>
<tr>
<td><strong>Mixed course by number of DTPw</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>1 dose of DTPw only</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose DTPa (n=549)</td>
<td>6</td>
<td>364.3</td>
<td><strong>3.22</strong> (1.15, 7.32)</td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose DTPw (n=2,501)</td>
<td>20</td>
<td>266.6</td>
<td>2.35 (1.36, 3.89)</td>
</tr>
<tr>
<td><strong>2+ doses of DTPw</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose DTPa (n=429)&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6</td>
<td>466.2</td>
<td><strong>4.12</strong> (1.47, 9.37)</td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; dose DTPw (n=4,432)&lt;sup&gt;c&lt;/sup&gt;</td>
<td>22</td>
<td>165.5</td>
<td>1.46 (0.87, 2.37)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Rate per 100,000 per year

<sup>b</sup> Only 2 children had 3 doses of DTwP ≤12 months of age

<sup>c</sup> Only 40 children had 3 doses of DTwP ≤12 months of age
Conclusions and possible explanations

• Infant priming with DTPw associated with lower risk of pertussis than priming with DTPa only, more than a decade following primary vaccination

• Most important factor may be the first vaccine received - recent evidence from Oregon, USA, concurs with our findings

• Different immune responses from acellular and whole-cell priming

• Linked epitope suppression
  – initial exposure “locks in” the immune response to certain epitopes,
  – inhibits response to other linked epitopes on subsequent exposure¹

Pertussis study 2: methods

- Linked pertussis notification (NOCS) and vaccination records (VIVAS)

- Screening method:

\[ VE = \left( 1 - \left( \frac{PCV}{1-PCV} \times \frac{1-PPV}{PPV} \right) \right) \times 100 \]
Discussion and conclusions

• Although less protective than whole-cell vaccine, acellular vaccine provided very good protection for young children against notification in 2009/2010

• Overall, enduring high - moderate level of protection in older children against notification in 2009/2010

• Why lower VE estimates in 2010?
  PCR detection of milder illness against which vaccine is less effective?
  True decrease in effectiveness?
Outcomes and benefits of pertussis research

• Improved understanding of current pertussis epidemiology and vaccine effectiveness both nationally and internationally

• Results shared in peer reviewed literature
Hepatitis B study: aims

• Describe the epidemiology of hepatitis B infection and hepatitis B vaccination coverage in Queensland

• Assess hepatitis B neonatal post-exposure prophylaxis/prevention program:
  – completeness in delivering hepatitis B immunoglobulin (HBIG) and hepatitis B vaccine birth dose to infants born to hep B +ve mothers
  – completeness of the infant hep B vaccination course among children born to B +ve mothers
  – number of children receiving serological testing through Pathology Queensland, of children born to hep B +ve mothers, by vaccination status
  – incidence of hep B infection among children born to hep B +ve mothers and fathers, by receipt of HBIG and/or vaccine,
  – incidence of vaccine failures, program failures or missed opportunities
Hep B study: methods

Data linkage by the Health Statistics Unit:

- NOCS
- VIVAS
- QHAPDC
- Auslab
- Perinatal data collection (PDC)
- Births, deaths and marriages (BDM)
Requested data linkage

Combine: QHAPDC → VIVAS → NOCS

To create: NOCS/QHAPDC/VIVAS

Then link:

- NOCS/QHAPDC/VIVAS
  - PDC*
  - QHAPDC*
  - Births
  - Auslab
  - NOCS/QHAPDC/VIVAS → Auslab
  - NOCS/QHAPDC/VIVAS → Auslab

Births →
- Mothers’ name
- Fathers’ names

NOCS/QHAPDC/VIVAS → Auslab

* PDC with unnamed data (prior to 1 July 2007 for public, from 1 July 2007 for private) to be linked to QHAPDC to obtain mother’s name & address
Expected benefits from data linked vaccine research

• Efficient use of routinely collected data to answer public health questions and evaluate large, expensive publicly funded vaccination programs

• Studies are providing previously unavailable results on vaccine effectiveness in Australia (sometimes internationally relevant) and contribute to vaccine program evaluation

• Provide evidence base to inform decision making related to vaccine programs and support improvements in vaccination programs for public health benefit
Acknowledgements

Statistical Analysis and Linkage Unit, QLD Health
Epidemiology and Surveillance, Communicable Diseases Unit, QLD Health

PhD supervisors: Stephen Lambert, Robert Ware, Keith Grimwood

QCMRI Clinical Scholarship, the Australian Government (Australian Postgraduate Award) (Jan 2012-Jun 2012), and the National Health and Medical Research Council (from 2013) for PhD funding support